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A B S T R A C T
Background: After 100 years of research, Chagas disease (CD) remains an important public health
problem in Latin America. The symptomatic chronic phase is usually characterized by cardiac or
digestive involvement and diagnosis currently relies on the measurement of Trypanosoma cruzi-speciﬁc
antibodies produced in response to the infection. However, the detection of parasite DNA in seronegative
persons has been reported.
Methods: The prevalence of CD in a population with esophageal disorders was assessed by conventional
serology. We also detected T. cruzi DNA in blood samples of seronegative and inconclusive patients by
nested polymerase chain reaction (N-PCR).
Results: The seroprevalence of CD determined by conventional serologic tests (indirect immunoﬂuo-
rescence (IIF) and enzyme-linked immunosorbent assay (ELISA)) was 79% in 513 patients with
esophageal disorders. Out of 41 blood samples, N-PCRwas positive in 31 (76%) cases forwhich serology
was negative or inconclusive.
Conclusions: As all patients presented with clinical signs suggestive of the digestive form of CD andmost
of them were born in endemic areas, we highlight the importance of improving diagnosis of the disease
and the implications for blood bank screening. Our data suggest that N-PCR is effective in the detection of
T. cruzi DNA in patients with inconclusive or negative serology, and it may eventually be useful in the
determination of the etiology of megaesophagus.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Trypanosoma cruzi is the etiologic agent of Chagas disease
(CD), a disease that currently affects approximately 12 million
persons, mainly in Latin America.1 However, increasing travel
and immigration have led to emerging cases in North America
and Europe.2–4 Despite efﬁcient vector control programs
launched in South America to restrict its spread and the
screening of blood banks, CD remains a challenging disease
and 40 million persons are at risk of infection.5 Parasites are
usually transmitted by a hematophagous species of triatomine
bug of the Reduviidae family. In June 2006, Brazil was formally
declared free of CD transmission by its main vector Triatoma
infestans, however other mechanisms of transmission remain,
including blood transfusion, congenital route, organ transplan-
tation, contaminated food, and laboratory accidents.6 The
clinical presentation of a chagasic infection is variable and* Corresponding author. Tel.: +55 19 35219215; fax: +55 19 32894107.
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genetic diversity of T. cruzi, and the host immune response. In the
early stages of infection, parasites can be detected in the
bloodstream and symptoms are usually mild and non-speciﬁc. The
chronic phase appears 2–4 months after infection and, initially, no
symptoms are observed; this clinical latency characterized by low
and intermittent parasitemiamay last throughout life. Up to 30% of
infected persons eventually develop clinical forms of the disease
with cardiac or digestive involvement, usually 10–15 years after
infection.7
Involvement of the digestive organs is mainly attributed to
neuronal damage induced by immune and inﬂammatory pro-
cesses elicited by the presence of T. cruzi.8 Megaesophagus and
megacolon are themost notable and extensively studied organs in
digestive CD, observed in about 15% of chronic patients in disease
endemic areas; these are common conditions in the western part
of the states of Minas Gerais and Goia´s in Brazil.9,10
Idiopathic megaesophagus and megacolon are rare conditions
in our country. For this reason, when such clinical forms are
observed and the patient has positive epidemiology for the disease,
Chagas etiology should be sought. Nevertheless, serodiagnosismayses. Published by Elsevier Ltd. All rights reserved.
Table 1
Epidemiologic and clinical characteristics of patients with negative or inconclusive
serologic ﬁndings (group 1)
Patient Age Sex Origin Clinical
forma
Treatment Last sero-
logic
tests
N-PCR
ELISA IIF
3 80 F EN ME S D D Positive
4 64 M EN ME II S P N Positive
5 51 F EN ME II S N N Positive
6 52 F EN ME II S N N Positive
7 57 M EN ME III – N N Positive
8 54 F EN ME S N N Positive
10 64 F EN ME I – N N Positive
12 40 M NON ME I – P N Positive
14 62 M EN ME I S N N Positive
15 44 M EN ME I – N N Positive
16 56 M EN ME S N N Positive
17 68 M EN ME II S N N Positive
18 52 F EN ME I – N N Positive
19 71 M EN ME, MC S P 1/20 Positive
20 51 M EN ME I, MC S N N Positive
22 63 M EN ME, MC S N N Positive
23 64 F NON ME II S N N Positive
25 71 M EN ME II S N N Positive
26 31 F NON ME I S N N Positive
28 36 M EN ME I S N N Positive
30 29 F EN ME S N N Positive
31 47 F EN ME I P N Positive
32 62 M EN ME II S P 1/10 Positive
33 33 F NON ME II S N N Positive
35 53 F EN ME I – N N Positive
36 59 M EN ME I – D D Positive
37 44 M EN ME I S N N Positive
38 55 F EN ME II S N N Positive
39 52 F EN ME I – N N Positive
40 62 M EN ME II S P 1/10 Positive
41 54 F EN ME II, MC S N N Positive
1 68 F EN ME II S N N Negative
9 27 F NON ME I S N N Negative
11 22 M NON ME I S N N Negative
13 21 F NON ME I S N N Negative
21 33 F EN ME I P N Negative
27 41 M EN ME I – P 1/10 Negative
34 33 M NON ME II S N N Negative
2 34 F EN ME I – P 1/10 Inconclusive
24 69 F EN ME I, MC P N Inconclusive
29 51 F EN ME I S N N Inconclusive
ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunoﬂuorescence; N-
PCR, nested-polymerase chain reaction; EN, disease endemic area; NON, disease
non-endemic area; ME, megaesophagus; MC, megacolon; S, surgery; P, positive; N,
negative; D, doubtful.
a Megaesophagus stage according to Rezende et al., 1960.17
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sometimes attributed empirically.11
Standard diagnosis in the chronic phase of CD relies on the
detection of IgG anti-T. cruzi by serologic tests. The use of a
complex mixture of parasite antigens in most conventional tests
increases the probability of false-positives because of cross-
reactivity with other protozoa.12 On the other hand, false-negative
results may also occur;13,14 this makes the diagnosis of T. cruzi
infection a challenge.
Alternative molecular approaches have been studied to
overcome the limitations of serodiagnosis. The development of
polymerase chain reaction (PCR)-based strategies has allowed an
accurate diagnosis of several etiologic agents. Many different
protocols have been described using T. cruzi kinetoplast DNA
(kDNA) and repeated satellite sequences as targets. Using a nested
PCR (N-PCR) for ampliﬁcation of a 149-bp satellite DNA fragment,
Marcon et al.15 reported a good speciﬁcity and sensitivity for
parasite detection in blood samples from chronic patients and
patients with doubtful serologic tests. Considering the difﬁculties
related to the differential diagnosis, in this study N-PCR was
employed to evaluate the efﬁcacy of this method for the detection
of T. cruzi DNA in the blood of patients with esophageal motility
disorders and, eventually, to clarify the disease etiology.
2. Patients and methods
2.1. Patients
A retrospective study was undertaken to investigate the
seroprevalence of T. cruzi in 513 persons with esophageal motility
disorders followed at the Clinical Hospital of the University of
Campinas from1999 to 2007. From this populationwe recruited 41
patients with negative or inconclusive conventional serologic tests
for CD (group 1). The diagnosis of megaesophagus was established
based on clinical data and radiological studies. In order to evaluate
the sensitivity of N-PCR we included two groups of seropositive
patients: 31with the digestive form of CD (group 2) and 14with an
indeterminate form of CD (group 3). Blood specimens from 18
healthy persons with no epidemiologic suspicion of CD were used
as negative control (group 4) to assure PCR speciﬁcity.
2.2. Serologic tests
For patients included in this study, two serologic assays with
different methodological principles were performed to detect T.
cruzi infection: indirect immunoﬂuorescence (IIF) and an enzyme-
linked immunosorbent assay (ELISA). Samples were classiﬁed
according to the status of the serologic tests: positive when IIF
1:40 and ELISA reactive, negative when IIF 1:40 and ELISA non-
reactive, and inconclusive if results did not ﬁt any of the previous
criteria.
2.3. DNA isolation and nested PCR assay
Genomic DNAwas isolated from4 ml of ETDA–peripheral blood
using the method previously described by Sambrook and Russel,16
with some modiﬁcations. After centrifugation, plasma was
immediately separated from blood cells. Red blood cells were
treated with a lysis buffer (0.0114 mol/l NH4Cl and 0.01 mol/l
NH4HCO3) and leukocytes were washed with TKM1 (10 mmol/l
Tris–HCl pH 7.6, 10 mmol/l KCl, 10 mmol/l MgCl2, 20 mmol/l
ethylenediaminetetraacetic acid (EDTA)). After centrifugation,
supernatant was removed and the pellet was washed with
TKM2 (10 mmol/l Tris–HCl pH 7.6, 10 mmol/l KCl, 0.4 mol/l NaCl,
10 mmol/l MgCl2, 2 mmol/l EDTA). Sodium dodecyl sulfate (SDS;
10%) was added and the samples were incubated at 55 8C for30 min. NaCl (5 mol/l) was added to the supernatant after
centrifugation. Following a phenol/chloroform extraction and
ethanol/sodium acetate 3 mol/l precipitation, DNA was washed
with 70% ethanol and resuspended in 30 ml of deionized and sterile
water. For N-PCR assays, 1ml of extracted DNA was ampliﬁed at
least in duplicate.
The N-PCR assay was based on a procedure described by
Marcon et al.15 DNA ampliﬁcation was carried out in a 20 ml
reaction mixture containing 10 mmol/l Tris (pH 8.3), 50 mmol/l
KCl, 1.5mmol/l MgCl2, 0.2mmol/l of each dNTP, 0.1mmol/l of each
primer, and 1 U of Taq DNA polymerase. For the ﬁrst reaction,
primers TCZ1 (forward 50-CGAGCTCTTGCCCACACGGGTGCT-30)
and TCZ2 (reverse 50-CCTCCAAGCAGCGGATAGTTCAGG-30) were
used and in the second round, 1ml of ampliﬁed DNA was re-
ampliﬁed using TCZ3 (forward 50-TGCTGCA(G/C)TCGGCTGATC-
GTTTTCGA-30) and TCZ4 (50-reverse CA(A/G)G(C/G)TTGTTTGGTG-
TCCAGTGTGTGA-30). Annealing temperatures used were 65 8C and
55 8C for the ﬁrst and second rounds, respectively. The 149-bp
amplicon was separated by electrophoresis on 2% agarose gel and
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green loading dye (LGC Bio). In addition, the b-globin gene was
ampliﬁed for each sample to check DNA quality and the absence of
inhibitors. To avoid false-positive results because of PCR contami-
nation, ﬁrst and second runs were set up in distinct laboratory
areas and a reaction mixture with no DNA was included in each
reaction set.
3. Results
The seroprevalence of CD determined by conventional serologic
tests (IIF and ELISA)was 79% (404/513) in patientswith esophageal
disorders. Results were inconclusive in 31/513 (6%) and negative in
78/513 (15%) samples. Forty-one patients (22 women and 19men)
with inconclusive and negative results were enrolled for repeat
serologic tests and to proceed with molecular assays. We
considered the results of serology obtained on the same day that
blood was collected for the PCR procedure as the most recent.
The clinical and epidemiologic proﬁles of patients included in
group 1 are shown in Table 1. Results of IIF and ELISAwere negative
for 29/41 (71%) samples and were inconclusive for 12/41 (29%). All
patients had megaesophagus and 5/41 (12%) also had megacolon.
Megaesophagus stage was determined according to Rezende et
al.17 in 35 cases: 21/35 (60%) corresponding to grade I, 13/35 (37%)
grade II, and 1/35 (3%) grade III. Cardiac abnormalities compatible
to chagasic cardiomyopathywere also found in at least 10/41 (24%)
patients.
T. cruzi DNAwas detected by N-PCR ampliﬁcation in 31 (76%) of
41 samples and was more frequently found in patients born in
disease endemic areas (n = 27 positive cases) than in those born in
non-endemic areas (n = 4 positive cases). When considering only
the seronegative patients, N-PCR was positive in 23/29 (79%)
samples. Among thosewith inconclusive conventional serology, N-
PCR was positive in 8/12 (67%) (Table 2). N-PCR was considered
inconclusive in three cases, which means disagreement among at
least four different results.
For patients included in group 2 and group 3, N-PCR was
positive in 29/31 and 13/14 samples, respectively (Table 3).
Considering N-PCR performance for both groups, sensitivity was
approximately 93.4% compared to conventional serology. No DNA
ampliﬁcation for all negative controls (group 4) assured the
speciﬁcity of N-PCR.Table 2
Comparison of conventional serology and N-PCR in patient group 1
N-PCR
Positive Negative Inconclusive
Negative serologic tests 29 23 5 1
Inconclusive serologic tests 12 8 2 2
Total 41 31 7 3
N-PCR, nested-polymerase chain reaction.
Table 3
N-PCR results for positive control groups
Control group N-PCR
Positive Negative Inconclusive Sensitivitya
Group 2 31 29 2 0 93.5%
Group 3 14 13 1 0 92.8%
Total 45 42 3 0 93.4%
N-PCR, nested-polymerase chain reaction.
a Compared to conventional serology.4. Discussion
After 100 years of research, CD remains an important public
health problem. Recent outbreaks of oral infection with T. cruzi in
Brazil and emerging cases in Europe and the USA due to migratory
movements are situations that require improvement in diagnostic
and clinical knowledge. The high seroprevalence of CD observed in
patientswith esophageal disorders in this study corroborates other
reports that suggest esophagopathy as a good marker of chagasic
infection in Brazil.10,18,19
Current laboratory criteria for characterizing patients with CD
are based on positive serologic tests. However, the determination
of infection status by serologic analysis has been found faulty and
may lead to misdiagnosis.20 PCR-based assays have been
exhaustively reported and they appear to be an efﬁcient method
for the reliable and easy detection of T. cruzi DNA,15,21–26
presenting high sensitivity when compared to other indirect
parasitological methods such as xenodiagnosis and hemocul-
ture.6,27–31 Occurring once in a large number of copies in the
genome, T. cruzi satellite DNA is an appropriate target for a speciﬁc
PCR-based diagnosis of CD in blood samples, which provides high
sensitivity.32 The high N-PCR positivity in samples from seroposi-
tive patients with digestive and indeterminate forms of CD in our
study suggests that this is an efﬁcient method to detect T. cruzi
DNA in blood samples from chronic patients. In addition, TCZ1 and
TCZ2 do not prime ampliﬁcation of sequences in other protozoa
phylogenetically closely related to T. cruzi, avoiding false-positive
results.
In the present study, the N-PCR ampliﬁcation of a T. cruzi
satellite DNA sequence yielded positive results in 76% of a
seronegative population with signs suggestive of the digestive
form of CD. Most of these patients (80%) were born in disease
endemic areas and reported other relatives infected. Previous
reports have detected positive PCR results in seronegative persons.
However, none of them established a clear correlation between
laboratory ﬁndings and speciﬁc clinical proﬁles.
In Brazil, positive PCR results were found in three seronegative
persons from a high disease endemic area of Minas Gerais.27
Studying serum samples from Bolivian children, Wincker et al.33
reported twopositive PCR results in 17 seronegative persons. Using
speciﬁc PCR for T. cruzi kDNA, 16 positive results were reported
among 34 persons with negative or inconclusive serology by
Gomes et al.34 Similarly, Castro et al.35 found three positive cases
among nine seronegative persons born in disease endemic areas
and one of them also had a positive blood culture. Salomone et
al.,13 studying anArgentinean population at epidemiologic risk and
with negative serologic ﬁndings for CD, reported 15% PCR-positive
cases.
When explaining the lack of association between PCR and
serologic results, authors tend to disregard contamination during
molecular assay procedures since all steps are carried out in
separated areas and negative controls are always used. Taking this
into account, some hypotheses have been suggested to explain this
controversial situation. A central point concerns the immune
response in patients infected by T. cruzi. Despite chronic infection,
a humoral response may not develop or be detected by
conventional serology in some patients. Bre´nie`re et al.36 reported
speciﬁc immunosuppression in seronegative persons with chronic
CD and asserted that some T. cruzi strains may not induce the
production of speciﬁc antibodies.
Regarding digestive involvement, a Brazilian study showed the
absence of speciﬁc antibodies veriﬁed by successive negative
conventional serologic tests in 26 persons from a population with
megaesophagus and epidemiologic antecedents for CD. In addition,
T. cruzi was detected by xenodiagnosis in two of the 26
seronegative samples.37 These reports highlight the possibility
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able only by PCR may be more common than expected. The high
seronegativity rate revealed in our study emphasizes the impor-
tance of improving diagnosis, especially in blood donor screening.
In summary, our ﬁndings suggest that, although serologic tests
may be performed for diagnostic purposes when a chagasic
infection is suspected, they may not be suitable in some particular
situations. Interestingly, some patients enrolled in our study had
cardiac abnormalities compatible with chagasic infection associ-
atedwith the digestivemanifestations.Wewish to emphasize that,
beyond serologic investigation, clinical and epidemiologic data
must be considered in the determination of the disease etiology.
Although PCR appears to be an efﬁcientmethod for the detection of
T. cruzi DNA, it also shows limited sensitivity in patients with very
low or intermittent parasitemia; moreover, distinct protocols may
lead to different results. Further standardization studies should be
encouraged in order to overcome technical limitations and to
validate PCR-based assays for the diagnosis of CD.
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